Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.
| Drug | Target | Relationship | GBM | LUAD | SCLC | LUSC | OAC | OSCC | PDAC | Reposition | #cancers |
|---|---|---|---|---|---|---|---|---|---|---|---|
| mitapivat, mitapivat-matching placebo, mitapivat-matching placebo | PKLR | Direct | 1 | ||||||||
| adagrasib | KRAS | SSL via KRAS | yes | 2 | |||||||
| sotorasib | KRAS | SSL via KRAS | yes | 2 | |||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | CSK | SSL via CSK | 3 | ||||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | LCK | SSL via LCK | 3 | ||||||||
| tucatinib | ERBB3 | SSL via ERBB3 | 3 | ||||||||
| bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment | CSK | SSL via CSK | 2 | ||||||||
| bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment | LCK | SSL via LCK | 2 | ||||||||
| nintedanib | LCK | SSL via LCK | 2 | ||||||||
| nintedanib, pembrolizumab | LCK | SSL via LCK | 2 | ||||||||
| afatinib, dasatinib, palbociclib, everolimus, olaparib | CSK | SSL via CSK | 1 | ||||||||
| afatinib, dasatinib, palbociclib, everolimus, olaparib | LCK | SSL via LCK | 1 | ||||||||
| azacitidine, vorinostat, gemcitabine, busulfan, melphalan, dexamethasone, caphosol, glutamine, pyridoxine, rituximab | NOS2 | SSL via NOS2 | 1 | ||||||||
| bevacizumab, dasatinib, placebo | CSK | SSL via CSK | 1 | ||||||||
| bevacizumab, dasatinib, placebo | LCK | SSL via LCK | 1 | ||||||||
| bosutinib | CAMK2G | SSL via CAMK2G | 1 | ||||||||
| byl719, poziotinib, nintedanib, abemaciclib, durvalumab,tremelimumab | LCK | SSL via LCK | 1 | ||||||||
| dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride | CSK | SSL via CSK | 1 | ||||||||
| dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride | LCK | SSL via LCK | 1 | ||||||||
| dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method | CSK | SSL via CSK | 1 | ||||||||
| dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method | LCK | SSL via LCK | 1 | ||||||||
| dasatinib, laboratory biomarker analysis, physiologic testing | CSK | SSL via CSK | 1 | ||||||||
| dasatinib, laboratory biomarker analysis, physiologic testing | LCK | SSL via LCK | 1 | ||||||||
| dasatinib, mfolfox6 | CSK | SSL via CSK | 1 | ||||||||
| dasatinib, mfolfox6 | LCK | SSL via LCK | 1 | ||||||||
| dasatinib, pharmacological study | CSK | SSL via CSK | 1 | ||||||||
| dasatinib, pharmacological study | LCK | SSL via LCK | 1 | ||||||||
| dasatinib, temozolomide, placebo, radiation therapy | CSK | SSL via CSK | 1 | ||||||||
| dasatinib, temozolomide, placebo, radiation therapy | LCK | SSL via LCK | 1 | ||||||||
| dexamethasone | NOS2 | SSL via NOS2 | 1 | ||||||||
| dexamethasone, fluorouracil, brachytherapy, phosphorus p32, radiation therapy | NOS2 | SSL via NOS2 | 1 | ||||||||
| dexamethasone, ondansetron, quality-of-life assessment | NOS2 | SSL via NOS2 | 1 | ||||||||
| disitamab vedotin, tucatinib | ERBB3 | SSL via ERBB3 | 1 | ||||||||
| docetaxel, 5-fu, radiotherapy, esophagectomy, dexamethasone | NOS2 | SSL via NOS2 | 1 | ||||||||
| gemcitabine, oxaliplatin, dexamethasone, floxuridine (fudr), implanted medical device | NOS2 | SSL via NOS2 | 1 | ||||||||
| minocycline, placebo, questionnaires | NOS2 | SSL via NOS2 | 1 | ||||||||
| pegph20, nab-paclitaxel, gemcitabine, dexamethasone, enoxaparin | NOS2 | SSL via NOS2 | 1 | ||||||||
| ponatinib | LCK | SSL via LCK | 1 | ||||||||
| temozolomide, aprepitant, minocycline, disulfiram, celecoxib, sertraline, captopril, itraconazole, ritonavir, auranofin | NOS2 | SSL via NOS2 | 1 | ||||||||
| tucatinib, trastuzumab, oxaliplatin, leucovorin, fluorouracil, capecitabine, pembrolizumab | ERBB3 | SSL via ERBB3 | 1 | ||||||||
| tucatinib, trastuzumab, ramucirumab, paclitaxel, tucatinib placebo, trastuzumab placebo | ERBB3 | SSL via ERBB3 | 1 | ||||||||
| dasatinib | LCK | SSL via LCK | yes | 0 | |||||||
| pazopanib | LCK | SSL via LCK | yes | 0 | |||||||
| pazopanib hydrochloride | LCK | SSL via LCK | yes | 0 | |||||||
| vandetanib | EPHB2 | SSL via EPHB2 | yes | 0 | |||||||
| vandetanib | ERBB3 | SSL via ERBB3 | yes | 0 | |||||||
| vandetanib | LCK | SSL via LCK | yes | 0 |